scholarly journals Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data

2015 ◽  
Vol 34 (21) ◽  
pp. 2881-2898 ◽  
Author(s):  
Yinghui Wei ◽  
Patrick Royston ◽  
Jayne F. Tierney ◽  
Mahesh K. B. Parmar
Keyword(s):  
Survival Time ◽  
Randomized Trials ◽  
Meta Analysis ◽  
Individual Participant Data ◽  
Time To Event ◽  
Mean Survival Time ◽  
Restricted Mean Survival Time ◽  
Individual Participant

OP236 Evidence Synthesis Of Time-To-Event Outcomes In The Presence Of Non-Proportional Hazards

2021 ◽  
Vol 37 (S1) ◽  
pp. 8-8
Author(s):  
Suzanne Freeman ◽  
Nicola Cooper ◽  
Alex Sutton ◽  
Michael Crowther ◽  
James Carpenter ◽  
...  
Keyword(s):  
Survival Time ◽  
Simulation Study ◽  
Proportional Hazards ◽  
Evidence Synthesis ◽  
Meta Analysis ◽  
Clinical Effectiveness ◽  
Time To Event ◽  
Mean Survival Time ◽  
Restricted Mean Survival Time

IntroductionSynthesis of clinical effectiveness is a well-established component of health technology assessment (HTA) combining data from multiple trials to obtain an overall pooled estimate of clinical effectiveness, which may inform an associated economic evaluation. Time-to-event outcomes are often synthesized using effect measures from Cox proportional hazards models assuming a constant hazard ratio over time. However, where treatment effects vary over time an assumption of proportional hazards is not always valid. Several methods have been proposed for synthesizing time-to-event outcomes in the presence of non-proportional hazards. However, guidance on choosing between these methods and the implications for HTA is lacking.MethodsWe applied five methods for estimating treatment effects from time-to-event outcomes, which relax the proportional hazards assumption to a network of melanoma trials, reporting overall survival: restricted mean survival time, an accelerated failure time generalized gamma model, piecewise exponential, fractional polynomial and Royston-Parmar models. We conducted a simulation study to compare these five methods. Simulated individual patient data was generated from a mixture Weibull distribution assuming a treatment-time interaction. Each simulated meta-analysis consisted of five trials with varying numbers of patients and length of follow-up across trials. For each model fitted to each dataset, we calculated the restricted mean survival time at the end of observed follow-up and following extrapolation to a 20-year time horizon.ResultsAll models fitted the melanoma data reasonably well with some variation in the treatment rankings and differences in the survival curves. The simulation study demonstrated the potential for different conclusions from different modelling approaches.ConclusionsThe restricted mean survival time, generalized gamma, piecewise exponential, fractional polynomial and Royston-Parmar models can all accommodate non-proportional hazards and differing lengths of trial follow-up within an evidence synthesis of time-to-event outcomes. Further work is needed in this area to extend the simulation study to the network meta-analysis setting and provide guidance on the key considerations for informing model choice for the purposes of HTA.

Restricted mean survival time as a summary measure of time‐to‐event outcome

2020 ◽  
Vol 19 (4) ◽  
pp. 436-453 ◽  
Author(s):  
Takahiro Hasegawa ◽  
Saori Misawa ◽  
Shintaro Nakagawa ◽  
Shinichi Tanaka ◽  
Takanori Tanase ◽  
...  
Keyword(s):  
Survival Time ◽  
Time To Event ◽  
Summary Measure ◽  
Mean Survival Time ◽  
Restricted Mean Survival Time

472: Progestogen in twin pregnancies: an individual participant data meta-analysis of randomized trials

2012 ◽  
Vol 206 (1) ◽  
pp. S215-S216 ◽  
Author(s):  
E. Schuit ◽  
Sarah Stock ◽  
Dwight Rouse ◽  
A.C. Lim ◽  
Line Rode ◽  
...  
Keyword(s):  
Randomized Trials ◽  
Meta Analysis ◽  
Individual Participant Data ◽  
Individual Participant ◽  
Twin Pregnancies

scholarly journals Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study

PLoS ONE ◽  
2016 ◽  
Vol 11 (3) ◽  
pp. e0150032 ◽  
Author(s):  
Béranger Lueza ◽  
Audrey Mauguen ◽  
Jean-Pierre Pignon ◽  
Oliver Rivero-Arias ◽  
Julia Bonastre ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Survival Time ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Cost Effectiveness Analysis ◽  
Patient Data ◽  
Mean Survival Time ◽  
Effectiveness Analysis ◽  
Restricted Mean Survival Time
Sign in / Sign up

Export Citation Format

Share Document